Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.

Author: , BrottoLori, BrundageMichael, CasadoHerraez A, CervantesAndres, EisenhauerElizabeth, HoskinsPaul, PovedaA, TuDongsheng, VergoteIgnace

Paper Details 
Original Abstract of the Article :
A recent phase III trial compared the efficacy of cisplatin-topotecan (a topoisomerase I inhibitor) followed by carboplatin-paclitaxel (Arm 1) versus paclitaxel-carboplatin (Arm 2) in women with newly diagnosed stage IIB or greater ovarian cancer. There was a significantly lower response rate in the...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/s00520-015-2873-8

データ提供:米国国立医学図書館(NLM)

Ovarian Cancer: Comparing Treatment Regimens and Quality of Life

Ovarian cancer is a complex and challenging disease. This study, like a camel navigating a vast and uncertain desert, compares two different treatment regimens for women with newly diagnosed stage IIB or greater ovarian cancer. The researchers conducted a phase III trial comparing the efficacy of cisplatin-topotecan followed by carboplatin-paclitaxel (Arm 1) versus paclitaxel-carboplatin (Arm 2). Their findings revealed that the experimental arm (Arm 1) had a significantly lower response rate and less likelihood of normalized CA125 within the first 3 months compared to the standard treatment (Arm 2). Although there were no significant group differences in progression-free survival at 43 months follow-up, the experimental arm was associated with significantly more side effects.

Optimizing Ovarian Cancer Treatment: Balancing Efficacy and Quality of Life

The study's findings highlight the importance of balancing efficacy and quality of life in ovarian cancer treatment. The researchers observed that the experimental arm, while not inferior in terms of progression-free survival, was associated with a lower response rate and more side effects. This finding underscores the need for individualized treatment plans that consider both the effectiveness of the treatment and its impact on the patient's overall well-being.

Living with Ovarian Cancer: Prioritizing Patient Needs

The study's findings emphasize the importance of patient-centered care in managing ovarian cancer. The researchers' findings highlight the need to consider not only the efficacy of treatment but also its impact on the patient's quality of life. This approach underscores the importance of open communication between patients and their healthcare providers to ensure that treatment plans are tailored to individual needs.

Dr.Camel's Conclusion

This study, like a camel navigating a vast and uncertain desert, highlights the importance of balancing efficacy and quality of life in ovarian cancer treatment. The researchers' findings suggest that individualized treatment plans that consider both the effectiveness of the treatment and its impact on the patient's overall well-being are essential. The camel of medicine continues to search for the perfect oasis of treatment, one that offers both efficacy and safety for patients with ovarian cancer, while prioritizing patient needs and quality of life.

Date :
  1. Date Completed 2016-09-26
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26304156

DOI: Digital Object Identifier

10.1007/s00520-015-2873-8

Related Literature

Article Analysis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.